NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

Heather H. Cheng; Veda N. Giri; Michael Goggins; Matthew B. Yurgelun; Beth Y. Karlan; Barbara S. Norquist; Mary B. Daly; Tuya Pal; Zahraa AlHilli; Banu Arun; Jane Churpek; Sarah Colonna; Susan M. Domchek; Mauricio R. Escobar; Laura Fejerman; Susan Friedman; Andrea Hagemann; Ashley Hendrix; Dezheng Huo; Mollie L. Hutton; Nawal Kassem; Seema Khan; Allison W. Kurian; Christine Laronga; Julie S. Mak; Kara N. Maxwell; Kevin McDonnell; Sofia D. Merajver; Jacqueline Mersch; Kenneth Offit; Jennifer Plichta; Dominique Rash; Gwen Reiser; Leigha Senter-Jamieson; Kristen Mahoney Shannon; Jeanna Welborn; Myra J. Wick; Marie Wood; Susan Darlow; Zeenat Diwan; Mary Dwyer

doi:10.6004/jnccn.2026.0007

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

Heather H. Cheng
, Veda N. Giri
, Michael Goggins
, Matthew B. Yurgelun
, Beth Y. Karlan
, Barbara S. Norquist
, Mary B. Daly
, Tuya Pal
, Zahraa AlHilli
, Banu Arun
, Jane Churpek
, Sarah Colonna
, Susan M. Domchek
, Mauricio R. Escobar
, Laura Fejerman
, Susan Friedman
, Andrea Hagemann
, Ashley Hendrix
, Dezheng Huo
, Mollie L. Hutton

Nawal Kassem, Seema Khan, Allison W. Kurian, Christine Laronga, Julie S. Mak, Kara N. Maxwell, Kevin McDonnell, Sofia D. Merajver, Jacqueline Mersch, Kenneth Offit, Jennifer Plichta, Dominique Rash, Gwen Reiser, Leigha Senter-Jamieson, Kristen Mahoney Shannon, Jeanna Welborn, Myra J. Wick, Marie Wood, Susan Darlow, Zeenat Diwan, Mary Dwyer

Fred Hutchinson Cancer Research Center
Yale University
Johns Hopkins University
Dana-Farber/Brigham and Women's Cancer Center
University of California at Los Angeles
Fox Chase Cancer Center
Vanderbilt University
Cleveland Clinic Foundation
University of Texas MD Anderson Cancer Center
University of Wisconsin Carbone Cancer Center
University of Utah
University of Pennsylvania
O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham
UC Davis Comprehensive Cancer Center
FORCE: Facing Our Risk of Cancer Empowered
University of Washington
University of Tennessee Health Science Center
UChicago Medicine Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Stanford Cancer Institute
Moffitt Cancer Center
UCSF Helen Diller Family Comprehensive Cancer Center
City of Hope National Medical Center
University of Michigan Rogel Cancer Center
UT Southwestern Simmons Comprehensive Cancer Center
Memorial Sloan-Kettering Cancer Center
Duke Cancer Institute
University of California at San Diego
Fred & Pamela Buffett Cancer Center
Ohio State University
Mass General Cancer Center
Mayo Clinic Comprehensive Cancer Center
University of Colorado Cancer Center
National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.

Original language	English
Pages (from-to)	2-10
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	24
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2026.0007
State	Published - Feb 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Breast Neoplasms/genetics
Early Detection of Cancer/standards
Female
Genetic Counseling/standards
Genetic Predisposition to Disease
Genetic Testing/standards
Humans
Male
Ovarian Neoplasms/genetics
Pancreatic Neoplasms/genetics
Prostatic Neoplasms/genetics
Risk Assessment

Access to Document

10.6004/jnccn.2026.0007

Cite this

Cheng, H. H., Giri, V. N., Goggins, M., Yurgelun, M. B., Karlan, B. Y., Norquist, B. S., Daly, M. B., Pal, T., AlHilli, Z., Arun, B., Churpek, J., Colonna, S., Domchek, S. M., Escobar, M. R., Fejerman, L., Friedman, S., Hagemann, A., Hendrix, A., Huo, D., ... Dwyer, M. (2026). NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026. JNCCN Journal of the National Comprehensive Cancer Network, 24(2), 2-10. https://doi.org/10.6004/jnccn.2026.0007

@article{c715c3df83b448a2a5cc4f1d00780106,

title = "NCCN Guidelines{\textregistered} Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel{\textquoteright}s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.",

keywords = "Breast Neoplasms/genetics, Early Detection of Cancer/standards, Female, Genetic Counseling/standards, Genetic Predisposition to Disease, Genetic Testing/standards, Humans, Male, Ovarian Neoplasms/genetics, Pancreatic Neoplasms/genetics, Prostatic Neoplasms/genetics, Risk Assessment",

author = "Cheng, \{Heather H.\} and Giri, \{Veda N.\} and Michael Goggins and Yurgelun, \{Matthew B.\} and Karlan, \{Beth Y.\} and Norquist, \{Barbara S.\} and Daly, \{Mary B.\} and Tuya Pal and Zahraa AlHilli and Banu Arun and Jane Churpek and Sarah Colonna and Domchek, \{Susan M.\} and Escobar, \{Mauricio R.\} and Laura Fejerman and Susan Friedman and Andrea Hagemann and Ashley Hendrix and Dezheng Huo and Hutton, \{Mollie L.\} and Nawal Kassem and Seema Khan and Kurian, \{Allison W.\} and Christine Laronga and Mak, \{Julie S.\} and Maxwell, \{Kara N.\} and Kevin McDonnell and Merajver, \{Sofia D.\} and Jacqueline Mersch and Kenneth Offit and Jennifer Plichta and Dominique Rash and Gwen Reiser and Leigha Senter-Jamieson and Shannon, \{Kristen Mahoney\} and Jeanna Welborn and Wick, \{Myra J.\} and Marie Wood and Susan Darlow and Zeenat Diwan and Mary Dwyer",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2026",

month = feb,

doi = "10.6004/jnccn.2026.0007",

language = "English",

volume = "24",

pages = "2--10",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "2",

}

Cheng, HH, Giri, VN, Goggins, M, Yurgelun, MB, Karlan, BY, Norquist, BS, Daly, MB, Pal, T, AlHilli, Z, Arun, B, Churpek, J, Colonna, S, Domchek, SM, Escobar, MR, Fejerman, L, Friedman, S, Hagemann, A, Hendrix, A, Huo, D, Hutton, ML, Kassem, N, Khan, S, Kurian, AW, Laronga, C, Mak, JS, Maxwell, KN, McDonnell, K, Merajver, SD, Mersch, J, Offit, K, Plichta, J, Rash, D, Reiser, G, Senter-Jamieson, L, Shannon, KM, Welborn, J, Wick, MJ, Wood, M, Darlow, S, Diwan, Z & Dwyer, M 2026, 'NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026', JNCCN Journal of the National Comprehensive Cancer Network, vol. 24, no. 2, pp. 2-10. https://doi.org/10.6004/jnccn.2026.0007

TY - JOUR

T1 - NCCN Guidelines® Insights

T2 - Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

AU - Cheng, Heather H.

AU - Giri, Veda N.

AU - Goggins, Michael

AU - Yurgelun, Matthew B.

AU - Karlan, Beth Y.

AU - Norquist, Barbara S.

AU - Daly, Mary B.

AU - Pal, Tuya

AU - AlHilli, Zahraa

AU - Arun, Banu

AU - Churpek, Jane

AU - Colonna, Sarah

AU - Domchek, Susan M.

AU - Escobar, Mauricio R.

AU - Fejerman, Laura

AU - Friedman, Susan

AU - Hagemann, Andrea

AU - Hendrix, Ashley

AU - Huo, Dezheng

AU - Hutton, Mollie L.

AU - Kassem, Nawal

AU - Khan, Seema

AU - Kurian, Allison W.

AU - Laronga, Christine

AU - Mak, Julie S.

AU - Maxwell, Kara N.

AU - McDonnell, Kevin

AU - Merajver, Sofia D.

AU - Mersch, Jacqueline

AU - Offit, Kenneth

AU - Plichta, Jennifer

AU - Rash, Dominique

AU - Reiser, Gwen

AU - Senter-Jamieson, Leigha

AU - Shannon, Kristen Mahoney

AU - Welborn, Jeanna

AU - Wick, Myra J.

AU - Wood, Marie

AU - Darlow, Susan

AU - Diwan, Zeenat

AU - Dwyer, Mary

PY - 2026/2

Y1 - 2026/2

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.

KW - Breast Neoplasms/genetics

KW - Early Detection of Cancer/standards

KW - Female

KW - Genetic Counseling/standards

KW - Genetic Predisposition to Disease

KW - Genetic Testing/standards

KW - Humans

KW - Male

KW - Ovarian Neoplasms/genetics

KW - Pancreatic Neoplasms/genetics

KW - Prostatic Neoplasms/genetics

KW - Risk Assessment

UR - https://www.scopus.com/pages/publications/105029988274

U2 - 10.6004/jnccn.2026.0007

DO - 10.6004/jnccn.2026.0007

M3 - Article

C2 - 41671423

AN - SCOPUS:105029988274

SN - 1540-1405

VL - 24

SP - 2

EP - 10

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this